ALKBH5-YTHDF2 m6A modification axis inhibits rheumatoid arthritis progression by suppressing NLRP3

Xiao, Jianwei; Cai, Xu; Wang, Rongsheng; Zhou, Wei; Ye, Zhizhong

doi:10.1016/j.bbrc.2023.05.087

Cited by 4 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, Xu et al reported that ALKBH5 and YTHDF2 regulated m6A modification of MYO1C and contributed to synovial aggression and joint destruction in RA [ 110 ]. Mechanistically, ALKBH5 enhances JARID2 mRNA stability through IGF2BP3 and suppressed NLRP3 mRNA expression in cooperation with YTHDF2 are crucial for proliferation, migration, and invasion of RA FLSs [ 108 , 111 ].…”

Section: M6a and Skeletal System Diseasementioning

confidence: 99%

“…METTL14 silencing was proved to relieve RA progression through LASP1/SRC/AKT signaling pathway [ 107 ]. And Xiao et al reported that ALKBH5 inhibited RA progression by suppressing NLRP3 through YTHDC2 [ 111 ]. These findings provide novel sights for developing clinical treatment strategies targeting METTL3, METTL14 and ALKBH5.…”

Section: M6a and Skeletal System Diseasementioning

confidence: 99%

See 1 more Smart Citation

Recent advances of m6A methylation in skeletal system disease

Liang,

Yi,

Liu

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Skeletal system disease (SSD) is defined as a class of chronic disorders of skeletal system with poor prognosis and causes heavy economic burden. m6A, methylation at the N6 position of adenosine in RNA, is a reversible and dynamic modification in posttranscriptional mRNA. Evidences suggest that m6A modifications play a crucial role in regulating biological processes of all kinds of diseases, such as malignancy. Recently studies have revealed that as the most abundant epigentic modification, m6A is involved in the progression of SSD. However, the function of m6A modification in SSD is not fully illustrated. Therefore, make clear the relationship between m6A modification and SSD pathogenesis might provide novel sights for prevention and targeted treatment of SSD. This article will summarize the recent advances of m6A regulation in the biological processes of SSD, including osteoporosis, osteosarcoma, rheumatoid arthritis and osteoarthritis, and discuss the potential clinical value, research challenge and future prospect of m6A modification in SSD.

show abstract

Section: M6a and Skeletal System Diseasementioning

confidence: 99%

Section: M6a and Skeletal System Diseasementioning

confidence: 99%